Suvaxyn CSF Marker (--) - Lyophilisate and solvent for suspension for injection

Authorised

- Bovine viral diarrhoea virus, strain CP7_E2alf (E2 deleted), expressing E2 glycoprotein gene of classical swine fever virus (strain Alfort 187), Live

Product identification

Medicine name:
Suvaxyn CSF Marker (--) - Lyophilisate and solvent for suspension for injection

Active substance:
Bovine viral diarrhoea virus, strain CP7_E2alf (E2 deleted), expressing E2 glycoprotein gene of classical swine fever virus (strain Alfort 187), Live

Target species:
Pig

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Bovine viral diarrhoea virus, strain CP7_E2alf (E2 deleted), expressing E2 glycoprotein gene of classical swine fever virus (strain Alfort 187), Live

Presentation_strength:$10^{4.8}$ to $10^{6.5}$ $TCID_{50}$ Reference:Hse Index:0

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Pig**

  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AD04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Vial (glass), Package_size:Lyophilisate: 1 vial + solvent:1 vial, Content:Lyophilisate: 50 doses; solvent:50 ml

Packaging:Vial (glass), Package_size:Lyophilisate: 1 vial + solvent:1 vial, Content:Lyophilisate: 10 doses; solvent:10 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium SA

Marketing authorisation date:
10/02/2015

Manufacturing sites for batch release:
Zoetis Belgium

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
10/02/2015

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 8/01/2024
Download

ema-puar-suvaxyn-csf-marker-v-2757-par-en.pdf

ema-puar-suvaxyn-csf-marker-v-2757-var-ii-09-en.pdf
